Hepatology最新文献_第7页

Reply: Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for HCC 回复：脂质代谢重编程的全面剖析拓展了治疗 HCC 的精准医学

IF 13.5 1区医学

Hepatology Pub Date : 2025-04-21 DOI: 10.1097/hep.0000000000001364

Qingbin Liu, Jingjing Qi, Yong Yu, Shulong Jiang

引用次数: 0

Erratum: Late breaking abstracts 勘误：最新摘要

IF 13.5 1区医学

Hepatology Pub Date : 2025-04-21 DOI: 10.1097/hep.0000000000001323

Philip Newsome, Arun Sanyal, Iris Kliers, Laura Østergaard, Michelle Long, Mette Kjær, Anna M.G. Cali, Elisabetta Bugianesi, Mary Rinella, Michael Roden, Vlad Ratziu

引用次数: 0

Increased risk of hepatocellular carcinoma in HBeAg-negative indeterminate phase compared to HBeAg-negative chronic infection 与hbeag阴性慢性感染相比，hbeag阴性不确定期肝细胞癌的风险增加

IF 13.5 1区医学

Hepatology Pub Date : 2025-04-21 DOI: 10.1097/hep.0000000000001354

Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Junlong Dai, Yee-Kit Tse, Mandy Sze-Man Lai, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

{"title":"Increased risk of hepatocellular carcinoma in HBeAg-negative indeterminate phase compared to HBeAg-negative chronic infection","authors":"Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Junlong Dai, Yee-Kit Tse, Mandy Sze-Man Lai, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip","doi":"10.1097/hep.0000000000001354","DOIUrl":"https://doi.org/10.1097/hep.0000000000001354","url":null,"abstract":"Background & Aims: The outcomes and benefits of antiviral therapy in patients with indeterminate phase HBeAg-negative chronic hepatitis B (CHB) are not well described in treatment guidelines. We examined hepatocellular carcinoma (HCC) risk among these patients. Approach & Results: We identified all non-cirrhotic treatment-naïve patients with HBeAg-negative CHB who received ≥1 test for hepatitis B virus (HBV) DNA and HBeAg. HBeAg-negative indeterminate phase included abnormal alanine aminotransferase (ALT ≥40 IU/L) and low HBV DNA (<2,000 IU/mL), or normal ALT (<40 IU/L) and high HBV DNA (≥2,000 IU/mL). Cox model evaluated relationship between HBV phase and HCC risk, with antiviral therapy as time-dependent variable. In 17,287 patients (mean age 54.1 years, 50% male), 4,071 (24%) transitioned to HBeAg-negative chronic hepatitis, 8,722 (50%) remained in the indeterminate phase, and 4,494 (26%) moved to HBeAg-negative chronic infection over a median follow-up of 55.1 [interquartile range 21.3-105.4] months. Patients in the indeterminate phase had a significantly higher HCC risk than those in chronic infection (adjusted hazard ratio [aHR] 1.587, 95% CI 1.262-1.995). Among patients in the indeterminate phase, those with normal ALT and high HBV DNA had a higher HCC risk than those with abnormal ALT and low HBV DNA (aHR 1.377, 95% CI 1.007-1.883, p=0.045). The 5-year cumulative HCC incidence showed no significant difference between treated and untreated patients in either group. Conclusions: In patients with indeterminate phase HBeAg-negative CHB, those with normal ALT and high HBV DNA showed a higher HCC risk than those with abnormal ALT and low HBV DNA, with no difference between treated and untreated patients in either group. Close monitoring with timely antiviral treatment may suffice to mitigate HCC risk in untreated patients.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"29 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Privacy and fidelity: The promise of synthetic data in hepatology research 隐私与保真：肝病学研究中合成数据的前景

IF 13.5 1区医学

Hepatology Pub Date : 2025-04-21 DOI: 10.1097/hep.0000000000001361

Oren K. Fix, Michael Kane, Christina S. Gainey, Saif Khairat

引用次数: 0

Reply: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase 慢性乙型肝炎免疫耐受期患者乙型肝炎表面抗原与肝细胞癌风险的关系

IF 13.5 1区医学

Hepatology Pub Date : 2025-04-21 DOI: 10.1097/hep.0000000000001366

Tai-Chung Tseng, Jia-Horng Kao

引用次数: 0

Letter to the Editor: Dynamic frailty trajectories and temporal measurement challenges in assessing Liver Transplantation survival benefit 致编辑的信：动态衰弱轨迹和评估肝移植生存益处的时间测量挑战